Upcoming updates
for 2026-2027

November 2026

Management of Complex ADHD – Interview

To Be Announced
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Quick Take Vol. 94

Scott R. Beach, M.D., Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Pharmacotherapy for Cannabis Use Disorder

Joao P. De Aquino, M.D., Yale University School of Medicine
Included in Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Memberships.
December 2026

Aripiprazole Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Quick Take Vol. 95

Scott R. Beach, M.D., Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Citalopram and Escitalopram: A Summary of Key Differences and Similarities (2026 Update)

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.
January 2027

The Psychopharmacology Algorithm for Psychotic Depression

David Osser, M.D., Harvard Medical School
Included in Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Memberships.

Lithium Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Quick Take Vol. 96

Scott R. Beach, M.D., Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Psychopharmacology in Adults with Intellectual Disability: When to Prescribe, When to Stop

To Be Announced
Included in Silver, Gold, Silver extended or Gold extended Memberships.
February 2027

Atomoxetine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Quick Take Vol. 97

Scott R. Beach, M.D., Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Fluvoxamine Practical Guide: Pharmacology, Indications, Dosing Guidelines, and Adverse Effects (2027 Update)

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.
March 2027

Pharmacotherapy of Substance Use Disorders in Pregnancy

To Be Announced
Included in Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Memberships.

Methylphenidate Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Psychopharmacology of Weight Gain and Obesity

To Be Announced
Included in Silver, Gold, Silver extended or Gold extended Memberships.
April 2027

Too Much, Too Many: Dose Ceilings and Polypharmacy in Psychiatric Prescribing

Christopher Keary, M.D., Harvard Medical School & Lurie Center for Autism at Massachusetts General Hospital for Children
Included in Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Memberships.

Quick Take Vol. 98

Oliver Freudenreich, M.D., F.A.C.L.P., Massachusetts General Hospital – Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Amphetamines Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Venlafaxine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects (2027 Update)

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.
May 2027

Psychopharmacology of Autism

Christopher Keary, M.D., Harvard Medical School & Lurie Center for Autism at Massachusetts General Hospital for Children
Included in Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Memberships.

Quick Take Vol. 99

Oliver Freudenreich, M.D., F.A.C.L.P., Massachusetts General Hospital – Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.

ADHD Medications: A Comprehensive Formulations Guide

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.
June 2027

Bipolar Disorder in the Perinatal Period (2nd Edition)

To Be Announced
Included in Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Memberships.

Quick Take Vol. 100

Scott R. Beach, M.D., Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.
July 2027

Quick Take Vol. 101

Scott R. Beach, M.D., Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Desvenlafaxine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects (2027 Update)

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.
August 2027

Quick Take Vol. 102

Scott R. Beach, M.D., Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.
September 2027

Quick Take Vol. 103

Scott R. Beach, M.D., Harvard Medical School
Included in Silver, Gold, Silver extended or Gold extended Memberships.

Duloxetine Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects (2027 Update)

Sebastián Malleza, M.D., Psychopharmacology Institute
Included in Silver, Gold, Silver extended or Gold extended Memberships.
October 2027

CME Information

Physicians – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Nursing professionals – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour. 

All of our content is psychopharmacology, so the pharmacology hours shown on your certificate match the credits awarded for that activity. Your certificate states them on their own line, separately from the credit designation statement.

This applies to APRN pharmacology renewal as well. Boards of nursing define pharmacology CE in their own way, so please confirm with your board that this is the documentation they expect.

Download Accreditation Information (PDF)

Physician assistants – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The NCCPA accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME toward PA certification maintenance. Requirements are set by the NCCPA, so please confirm with them what your current cycle requires.

Download Accreditation Information (PDF)

Physicians outside the United States – CME Accreditation Statement

AMA PRA Category 1 Credit™ may be awarded to any physician, whether or not they are licensed in the United States. The requirements are the same.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.

Whether these credits count toward your own national continuing education requirement is decided by your national medical chamber or society, and the rules differ from country to country. We recommend confirming with them before relying on the credits for a licensing or recertification requirement.

Self Assessment for MOC – Accreditation Statement
  • Psychopharmacology Institute Self-Assessment Program 2026

Dates: April 1, 2026 – April 1, 2029

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2026 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2025

Dates: April 1, 2025 – April 1, 2028

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2024

Dates: April 1, 2024 – April 1, 2027

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.